Study of TTI-622 in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label study designed to evaluate TTI-622 administered in
combination with Pegylated liposomal doxorubicin in patients with platinum-resistant ovarian
cancer. Approximately 50 patients will be enrolled in the study (this includes two phases,
the Dose Escalation and Dose Expansion).